

DCEP/IXB

**syncor**

United States  
Nuclear Regulatory Commission Region III  
Attn: R.J. Caniano  
Chief, Nuclear Materials Safety  
799 Roosevelt Road  
Glen Ellyn, Illinois 60137

03017684

Dear Sir:

This statement is in response to the violation recieved by license No. 22-19174-01MD dated Febuary 5, 1990. This violation dealt with labeling of pharmaceuticals which did not contain correct information which described the pharmaceuticals chemical form (misadministrations)

We have taken a number of corrective steps to remedy this situation. Corrective actions taken to date are as follows:

1. Thirteen Viox clear leaded glass containers are now in use.
2. A consideration when choosing radiopharmaceutical kits has been dissimilarity of physical appearance.
3. The setup of our lab is such that different drugs are separated by various barriers.
4. The employee involved in most of the misadministrations was placed on a one year probation. During this period termination would have been a probability if any further misadministrations occurred (none occurred). A condition of the probation was that he see a psycologist about this problem.
5. "Superkits" are no longer compounded at our pharnaacy.

Since these corrective actions have been in effect we have experienced one mishap.. 11/7/89 DTPA labelled as MDP.

The corrective step we will be taking is another written warning to the employee involved with the majority of the misadministrations. The probation period will be one year. Another misadministration may end this employees career with Syncor.

We will be in full compliance as of March 5, 1990.

3-1-90  
Dated

*David Ziolkowski*  
David Ziolkowski RPH BCNP  
Manager, Syncor St. Paul, MN



*Innovators in high-tech pharmacy services*

Syncor International Corporation • 2233 University Avenue, Suite 220 • St. Paul, MN 55114  
Medical Services Group • (612) 645-3000

9005020114 900301  
REG3 LIC30  
22-19174-01MD PDC

MAR 05 1990 110  
IE07